{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:34:55Z","timestamp":1790278495297,"version":"4.1.0"},"publisher-location":"Cham","reference-count":86,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030510886","type":"print"},{"value":"9783030510893","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/5584_2020_514","type":"book-chapter","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T06:02:34Z","timestamp":1586239354000},"page":"129-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2"],"prefix":"10.1007","author":[{"given":"Francesco","family":"Maranta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cianfanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cianflone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"514_CR1","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545\u20132559. https:\/\/doi.org\/10.1056\/NEJMoa0802743","journal-title":"N Engl J Med"},{"key":"514_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE et al (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225\u2013232. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00712.x","journal-title":"Kidney Int"},{"key":"514_CR3","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560\u20132572. https:\/\/doi.org\/10.1056\/NEJMoa0802987","journal-title":"N Engl J Med"},{"key":"514_CR4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/ehn018","volume":"29","author":"SS Anand","year":"2008","unstructured":"Anand SS, Islam S, Rosengren A et al (2008) Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 29:932\u2013940. https:\/\/doi.org\/10.1093\/eurheartj\/ehn018","journal-title":"Eur Heart J"},{"issue":"Suppl 2","key":"514_CR5","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.2337\/dc11-s239","volume":"34","author":"A Avogaro","year":"2011","unstructured":"Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP (2011) Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34(Suppl 2):S285\u2013S290. https:\/\/doi.org\/10.2337\/dc11-s239","journal-title":"Diabetes Care"},{"key":"514_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis. JAMA 287:2570. https:\/\/doi.org\/10.1001\/jama.287.19.2570","journal-title":"JAMA"},{"key":"514_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","volume":"54","author":"AK Bose","year":"2005","unstructured":"Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury. Diabetes 54:146\u2013151. https:\/\/doi.org\/10.2337\/diabetes.54.1.146","journal-title":"Diabetes"},{"key":"514_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.2337\/diacare.28.4.956","volume":"28","author":"AJM Boulton","year":"2005","unstructured":"Boulton AJM, Vinik AI, Arezzo JC et al (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956\u2013962. https:\/\/doi.org\/10.2337\/diacare.28.4.956","journal-title":"Diabetes Care"},{"key":"514_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2337\/dc07-9917","volume":"30","author":"JB Buse","year":"2007","unstructured":"Buse JB, Ginsberg HN, Bakris GL et al (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30:162\u2013172. https:\/\/doi.org\/10.2337\/dc07-9917","journal-title":"Diabetes Care"},{"key":"514_CR10","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.2337\/db15-1141","volume":"65","author":"A Cameron-Vendrig","year":"2016","unstructured":"Cameron-Vendrig A, Reheman A, Siraj MA et al (2016) Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis. Diabetes 65:1714\u20131723. https:\/\/doi.org\/10.2337\/db15-1141","journal-title":"Diabetes"},{"key":"514_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.2040-1124.2011.00131.x","volume":"2","author":"Z Cao","year":"2011","unstructured":"Cao Z, Cooper ME (2011) Pathogenesis of diabetic nephropathy. J Diabetes Investig 2:243\u2013247. https:\/\/doi.org\/10.1111\/j.2040-1124.2011.00131.x","journal-title":"J Diabetes Investig"},{"key":"514_CR12","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","volume":"359","author":"J-L Chiasson","year":"2002","unstructured":"Chiasson J-L, Josse RG, Gomis R et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072\u20132077. https:\/\/doi.org\/10.1016\/S0140-6736(02)08905-5","journal-title":"Lancet"},{"key":"514_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/dc10-1318","volume":"34","author":"DC Colayco","year":"2011","unstructured":"Colayco DC, Niu F, McCombs JS, Cheetham TC (2011) A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 34:77\u201383. https:\/\/doi.org\/10.2337\/dc10-1318","journal-title":"Diabetes Care"},{"key":"514_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2019","unstructured":"Cosentino F, Grant PJ, Aboyans V et al (2019) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"key":"514_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0140-6736(09)61969-3","volume":"375","author":"CJ Currie","year":"2010","unstructured":"Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481\u2013489. https:\/\/doi.org\/10.1016\/S0140-6736(09)61969-3","journal-title":"Lancet"},{"key":"514_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bjp.0703393","volume":"130","author":"AS De Vriese","year":"2000","unstructured":"De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM (2000) Endothelial dysfunction in diabetes. Br J Pharmacol 130:963\u2013974. https:\/\/doi.org\/10.1038\/sj.bjp.0703393","journal-title":"Br J Pharmacol"},{"key":"514_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977\u2013986. https:\/\/doi.org\/10.1056\/NEJM199309303291401","journal-title":"N Engl J Med"},{"key":"514_CR18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJA et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (Lond, Engl) 366:1279\u20131289. https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9","journal-title":"Lancet (Lond, Engl)"},{"key":"514_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa0808431","journal-title":"N Engl J Med"},{"key":"514_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","volume":"72","author":"BA Ference","year":"2018","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL (2018) Impact of lipids on cardiovascular health. J Am Coll Cardiol 72:1141\u20131156. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.046","journal-title":"J Am Coll Cardiol"},{"key":"514_CR21","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.2337\/diacare.27.10.2540","volume":"27","author":"DS Fong","year":"2004","unstructured":"Fong DS, Aiello LP, Ferris FL, Klein R (2004) Diabetic retinopathy. Diabetes Care 27:2540\u20132553. https:\/\/doi.org\/10.2337\/diacare.27.10.2540","journal-title":"Diabetes Care"},{"key":"514_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1161\/CIRCULATIONAHA.106.658948","volume":"115","author":"CS Fox","year":"2007","unstructured":"Fox CS, Coady S, Sorlie PD et al (2007) Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115:1544\u20131550. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.658948","journal-title":"Circulation"},{"key":"514_CR23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P G\u00e6de","year":"2008","unstructured":"G\u00e6de P, Lund-Andersen H, Parving H-H, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580\u2013591. https:\/\/doi.org\/10.1056\/NEJMoa0706245","journal-title":"N Engl J Med"},{"key":"514_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2019.1588886","volume":"15","author":"A Garcia-Ropero","year":"2019","unstructured":"Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ (2019) Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol 15:275\u2013285. https:\/\/doi.org\/10.1080\/17425255.2019.1588886","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"514_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"key":"514_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"},{"key":"514_CR27","first-page":"853","volume":"3","author":"HAR Hadi","year":"2007","unstructured":"Hadi HAR, Suwaidi JA (2007) Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 3:853\u2013876","journal-title":"Vasc Health Risk Manag"},{"key":"514_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, R\u00f6nnemaa T, Py\u00f6r\u00e4l\u00e4 K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229\u2013234. https:\/\/doi.org\/10.1056\/NEJM199807233390404","journal-title":"N Engl J Med"},{"key":"514_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519\u20131529. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"key":"514_CR30","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose Control in type 2 diabetes. N Engl J Med 359:1577\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa0806470","journal-title":"N Engl J Med"},{"key":"514_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","volume":"5","author":"RR Holman","year":"2017","unstructured":"Holman RR, Coleman RL, Chan JCN et al (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5:877\u2013886. https:\/\/doi.org\/10.1016\/S2213-8587(17)30309-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"514_CR32","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125\u20132135. https:\/\/doi.org\/10.1016\/S0140-6736(09)60953-3","journal-title":"Lancet"},{"key":"514_CR33","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/dc12-0719","volume":"36","author":"J Hong","year":"2013","unstructured":"Hong J, Zhang Y, Lai S et al (2013) Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36:1304\u20131311. https:\/\/doi.org\/10.2337\/dc12-0719","journal-title":"Diabetes Care"},{"key":"514_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2337\/dc10-2377","volume":"34","author":"ES Huang","year":"2011","unstructured":"Huang ES, Liu JY, Moffet HH, John PM, Karter AJ (2011) Glycemic Control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care 34:1329\u20131336. https:\/\/doi.org\/10.2337\/dc10-2377","journal-title":"Diabetes Care"},{"key":"514_CR35","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.241.19.2035","volume":"241","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA 241:2035\u20132038. https:\/\/doi.org\/10.1001\/jama.241.19.2035","journal-title":"JAMA"},{"key":"514_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.7326\/0003-4819-141-6-200409210-00006","volume":"141","author":"K-T Khaw","year":"2004","unstructured":"Khaw K-T, Wareham N, Bingham S et al (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 141:413. https:\/\/doi.org\/10.7326\/0003-4819-141-6-200409210-00006","journal-title":"Ann Intern Med"},{"key":"514_CR37","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1177\/0300060516675504","volume":"45","author":"A Kibel","year":"2017","unstructured":"Kibel A, Selthofer-Relatic K, Drenjancevic I et al (2017) Coronary microvascular dysfunction in diabetes mellitus. J Int Med Res 45:1901\u20131929. https:\/\/doi.org\/10.1177\/0300060516675504","journal-title":"J Int Med Res"},{"key":"514_CR38","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","volume":"169","author":"A Kooy","year":"2009","unstructured":"Kooy A, de Jager J, Lehert P et al (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169:616. https:\/\/doi.org\/10.1001\/archinternmed.2009.20","journal-title":"Arch Intern Med"},{"key":"514_CR39","volume-title":"Pathological basis of disease","author":"A Kumar","year":"2010","unstructured":"Kumar A, Fausto A, Robbins SL, Cotran RS (2010) Pathological basis of disease, 8th edn. Saunders Elsevier, Philadelphia","edition":"8"},{"key":"514_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12963-018-0166-4","volume":"16","author":"J Lin","year":"2018","unstructured":"Lin J, Thompson TJ, Cheng YJ et al (2018) Projection of the future diabetes burden in the United States through 2060. Popul Health Metrics 16:1\u20139","journal-title":"Popul Health Metrics"},{"key":"514_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1677\/JOE-08-0468","volume":"201","author":"H Liu","year":"2009","unstructured":"Liu H, Dear AE, Knudsen LB, Simpson RW (2009) A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 201:59\u201366. https:\/\/doi.org\/10.1677\/JOE-08-0468","journal-title":"J Endocrinol"},{"key":"514_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","volume":"16","author":"M Lorenz","year":"2017","unstructured":"Lorenz M, Lawson F, Owens D et al (2017) Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol 16:6. https:\/\/doi.org\/10.1186\/s12933-016-0490-6","journal-title":"Cardiovasc Diabetol"},{"key":"514_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL et al (2019) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"514_CR44","doi-asserted-by":"publisher","first-page":"l5003","DOI":"10.1136\/bmj.l5003","volume":"366","author":"DJ Magliano","year":"2019","unstructured":"Magliano DJ, Islam RM, Barr ELM et al (2019) Trends in incidence of total or type 2 diabetes: systematic review. BMJ 366:l5003. https:\/\/doi.org\/10.1136\/bmj.l5003","journal-title":"BMJ"},{"key":"514_CR45","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K et al (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839\u2013848. https:\/\/doi.org\/10.1056\/NEJMoa1616011","journal-title":"N Engl J Med"},{"key":"514_CR46","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","volume":"47","author":"SP Marso","year":"2006","unstructured":"Marso SP, Hiatt WR (2006) Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 47:921\u2013929. https:\/\/doi.org\/10.1016\/j.jacc.2005.09.065","journal-title":"J Am Coll Cardiol"},{"key":"514_CR47","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016a) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"514_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016b) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"514_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723\u2013732. https:\/\/doi.org\/10.1056\/NEJMoa1615692","journal-title":"N Engl J Med"},{"key":"514_CR50","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2337\/diacare.26.6.1895","volume":"26","author":"RE Maser","year":"2003","unstructured":"Maser RE, Mitchell BD, Vinik AI, Freeman R (2003) The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 26:1895\u20131901. https:\/\/doi.org\/10.2337\/diacare.26.6.1895","journal-title":"Diabetes Care"},{"key":"514_CR51","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009304","volume":"7","author":"RJ Mentz","year":"2018","unstructured":"Mentz RJ, Bethel MA, Merrill P et al (2018) Effect of once-weekly Exenatide on clinical outcomes according to baseline risk in patients with type 2 diabetes mellitus: insights from the EXSCEL Trial. J Am Heart Assoc 7:e009304. https:\/\/doi.org\/10.1161\/JAHA.118.009304","journal-title":"J Am Heart Assoc"},{"key":"514_CR52","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/hrt.2003.021014","volume":"90","author":"KP Morgan","year":"2004","unstructured":"Morgan KP, Kapur A, Beatt KJ (2004) Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. Heart 90:732\u2013738. https:\/\/doi.org\/10.1136\/hrt.2003.021014","journal-title":"Heart"},{"key":"514_CR53","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canaglifozin and cardiovascular and renal events in type 2 diabetes mellitus. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"514_CR54","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457\u20132471. https:\/\/doi.org\/10.1056\/NEJMoa072761","journal-title":"N Engl J Med"},{"key":"514_CR55","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1203858","journal-title":"N Engl J Med"},{"key":"514_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-017-0648-x","volume":"17","author":"M Packer","year":"2018","unstructured":"Packer M (2018) Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovasc Diabetol 17:9. https:\/\/doi.org\/10.1186\/s12933-017-0648-x","journal-title":"Cardiovasc Diabetol"},{"key":"514_CR57","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 37:2315\u20132381. https:\/\/doi.org\/10.1093\/eurheartj\/ehw106","journal-title":"Eur Heart J"},{"key":"514_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cmet.2012.11.012","volume":"17","author":"C Rask-Madsen","year":"2013","unstructured":"Rask-Madsen C, King GL (2013) Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab 17:20\u201333. https:\/\/doi.org\/10.1016\/j.cmet.2012.11.012","journal-title":"Cell Metab"},{"key":"514_CR59","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/jcm4091761","volume":"4","author":"NR Robles","year":"2015","unstructured":"Robles NR, Villa J, Gallego RH (2015) Non-proteinuric diabetic nephropathy. J Clin Med 4:1761\u20131773. https:\/\/doi.org\/10.3390\/jcm4091761","journal-title":"J Clin Med"},{"key":"514_CR60","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","volume":"125","author":"VL Roger","year":"2012","unstructured":"Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics\u20142012 update. Circulation 125:e2\u2013e220. https:\/\/doi.org\/10.1161\/CIR.0b013e31823ac046","journal-title":"Circulation"},{"key":"514_CR61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA 321:69\u201379. https:\/\/doi.org\/10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"514_CR62","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","volume":"59","author":"N Sattar","year":"2016","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ (2016) SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333\u20131339. https:\/\/doi.org\/10.1007\/s00125-016-3956-x","journal-title":"Diabetologia"},{"key":"514_CR63","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jacc.2017.04.014","volume":"69","author":"N Sattar","year":"2017","unstructured":"Sattar N, Petrie MC, Zinman B, Januzzi JL (2017) Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol 69:2646\u20132656. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.014","journal-title":"J Am Coll Cardiol"},{"key":"514_CR64","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"key":"514_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin E, Marinopoulos S, Berkenblit G et al (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421\u2013431. https:\/\/doi.org\/10.7326\/0003-4819-141-6-200409210-00007","journal-title":"Ann Intern Med"},{"key":"514_CR66","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa0908359","volume":"362","author":"E Selvin","year":"2010","unstructured":"Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800\u2013811. https:\/\/doi.org\/10.1056\/NEJMoa0908359","journal-title":"N Engl J Med"},{"key":"514_CR67","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K et al (2016) Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions. JAMA 316:1289\u20131297. https:\/\/doi.org\/10.1001\/jama.2016.13985","journal-title":"JAMA"},{"key":"514_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2337\/diab.44.4.369","volume":"44","author":"MP Stern","year":"1995","unstructured":"Stern MP (1995) Diabetes and cardiovascular disease: the \u201ccommon soil\u201d hypothesis. Diabetes 44:369\u2013374. https:\/\/doi.org\/10.2337\/diab.44.4.369","journal-title":"Diabetes"},{"key":"514_CR69","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405\u2013412. https:\/\/doi.org\/10.1136\/bmj.321.7258.405","journal-title":"BMJ"},{"key":"514_CR70","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11916-008-0034-1","volume":"12","author":"M Tavakoli","year":"2008","unstructured":"Tavakoli M, Mojaddidi M, Fadavi H, Malik RA (2008) Pathophysiology and treatment of painful diabetic neuropathy. Curr Pain Headache Rep 12:192\u2013197. https:\/\/doi.org\/10.1007\/s11916-008-0034-1","journal-title":"Curr Pain Headache Rep"},{"key":"514_CR71","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2337\/diacare.27.7.1605","volume":"27","author":"C-H Tseng","year":"2004","unstructured":"Tseng C-H (2004) Mortality and causes of death in a National Sample of diabetic patients in Taiwan. Diabetes Care 27:1605\u20131609. https:\/\/doi.org\/10.2337\/diacare.27.7.1605","journal-title":"Diabetes Care"},{"key":"514_CR72","unstructured":"U.S. Food and Drug Administration (2008) Guidance for industry diabetes mellitus \u2013 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at https:\/\/www.fda.gov\/regulatoryinformation\/search-fda-guidance-documents"},{"key":"514_CR73","unstructured":"U.S. Food and Drug Administration (2018) Guidance for industry: diabetes mellitus \u2013 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes"},{"key":"514_CR74","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998a) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837\u2013853","journal-title":"Lancet"},{"key":"514_CR75","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998b) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854\u2013865","journal-title":"Lancet"},{"key":"514_CR76","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2337\/diab.25.12.1129","volume":"25","author":"University Group Diabetes Program","year":"1976","unstructured":"University Group Diabetes Program (1976) A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 25:1129\u20131153. https:\/\/doi.org\/10.2337\/diab.25.12.1129","journal-title":"Diabetes"},{"key":"514_CR77","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA et al (2018) Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol 9:1575. https:\/\/doi.org\/10.3389\/fphys.2018.01575","journal-title":"Front Physiol"},{"key":"514_CR78","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61:2108\u20132117. https:\/\/doi.org\/10.1007\/s00125-018-4670-7","journal-title":"Diabetologia"},{"key":"514_CR79","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT et al (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 140:1693\u20131702. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042375","journal-title":"Circulation"},{"key":"514_CR80","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7326\/0003-4819-138-7-200304010-00018","volume":"138","author":"S Vijan","year":"2003","unstructured":"Vijan S, Hayward RA (2003) Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 138:593\u2013602. https:\/\/doi.org\/10.7326\/0003-4819-138-7-200304010-00018","journal-title":"Ann Intern Med"},{"key":"514_CR81","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7326\/0003-4819-140-8-200404200-00013","volume":"140","author":"S Vijan","year":"2004","unstructured":"Vijan S, Hayward RA, American College of Physicians (2004) Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140:650. https:\/\/doi.org\/10.7326\/0003-4819-140-8-200404200-00013","journal-title":"Ann Intern Med"},{"key":"514_CR82","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045\u20131057. https:\/\/doi.org\/10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"514_CR83","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMc1611290","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:1799\u20131802. https:\/\/doi.org\/10.1056\/NEJMc1611290","journal-title":"N Engl J Med"},{"key":"514_CR84","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","volume":"162","author":"WB White","year":"2011","unstructured":"White WB, Bakris GL, Bergenstal RM et al (2011) EXamination of CArdiovascular OutcoMes with AlogliptIN versus standard of CarE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE). Am Heart J 162:620\u2013626.e1. https:\/\/doi.org\/10.1016\/j.ahj.2011.08.004","journal-title":"Am Heart J"},{"key":"514_CR85","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"514_CR86","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"}],"container-title":["Advances in Experimental Medicine and Biology","Diabetes: from Research to Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2020_514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T01:20:34Z","timestamp":1604971234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/5584_2020_514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030510886","9783030510893"],"references-count":86,"URL":"https:\/\/doi.org\/10.1007\/5584_2020_514","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"8 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}